<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682743</url>
  </required_header>
  <id_info>
    <org_study_id>N-122-2020</org_study_id>
    <nct_id>NCT04682743</nct_id>
  </id_info>
  <brief_title>Prevention of Post-Operative Shivering</brief_title>
  <official_title>Efficacy of Ondansetron Versus Paracetamol for Prevention of Post-Operative Shivering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shivering and vasoconstriction are thermoregulatory mechanisms that are required to increase&#xD;
      core body temperature (BT) in patients with core hypothermia.&#xD;
&#xD;
      paracetamol is an antipyretic drug that has been in clinical use for a long time.13,14 It can&#xD;
      lower the BT of febrile and nonfebrile patients.&#xD;
&#xD;
      A previous study demonstrated that orally administered paracetamol can suppress in a&#xD;
      dose-dependent manner the increase in the BT of patients with acute ischemic stroke. However,&#xD;
      few studies have evaluated the effects of paracetamol on postoperative shivering.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">February 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of shivering</measure>
    <time_frame>UP TO 1 HOURE</time_frame>
    <description>60 min postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The assessment the core temperatures</measure>
    <time_frame>UP TO 24 HOURE</time_frame>
    <description>temperatures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative shivering scores</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>&quot;0&quot; indicated no shivering; &quot;1,&quot; piloerection or peripheral vasoconstriction, but no visible shivering; &quot;2,&quot; muscular activity in only 1 muscle group; &quot;3,&quot; muscular activity in &gt;1 muscle group, but not generalized; and &quot;4,&quot; shivering involving the whole body.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Post-Operative Shivering</condition>
  <arm_group>
    <arm_group_label>saline group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>paracetamol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>received intravenous one gram of paracetamol over a 15-minute period,</description>
    <arm_group_label>paracetamol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>received intravenous 8 mg of ondansetron over a 15-minute period.</description>
    <arm_group_label>ondansetron group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>received intravenous 0.9% normal saline over a 15-minute period.</description>
    <arm_group_label>saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients between 18-40 years.&#xD;
&#xD;
          -  ASA physical status I and II&#xD;
&#xD;
          -  Both genders&#xD;
&#xD;
          -  Patients scheduled for elective mega-liposuction surgery under combined general&#xD;
             epidural anesthesia&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patients who refused to participate in the study,&#xD;
&#xD;
          -  ASA physical status more than II,&#xD;
&#xD;
          -  any contraindications to regional anesthesia,&#xD;
&#xD;
          -  surgical duration less than two hours or exceeding six hours,&#xD;
&#xD;
          -  giving history of any of the following; allergy to the study medications used, system&#xD;
             impairment, alcohol abuse, any endocrine disease affecting body temperature such as&#xD;
             thyroid disorders,&#xD;
&#xD;
          -  any psychiatric or neurological disorders, convulsions, patient receiving vasodilators&#xD;
             or medications likely to alter thermoregulation,&#xD;
&#xD;
          -  Finally if their body temperature was recorded to surpass 37.5ºC or &lt;36.5°C before&#xD;
             enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cairo university</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Amr Samir Wahdan</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia, Pain management and Surgical ICU</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

